polycystic ovarian syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: Patients in this group will receive a 250 mg magnesium supplement from Simorgh Daroo Attar Company once a day for 10 weeks. Intervention 2: Control group: Patients
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Women over 18 and under 45 years old BMI between 18/5 to 30 Do not change the dose of the drug or start taking a new drug in the last two weeks Absence of menopause Taking vitamin and mineral supplements
Exclusion criteria
Exclusion criteria: Failure to follow nutritional recommendations and interventions Do not refer the person again in the next steps Change the dose of the drug or start taking a new drug that affects the study indicators Use of Minoxidil Having a specific disease that disrupts the study process Occurrence of menopause
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hyperandrogenism. Timepoint: Before and after the intervention. Method of measurement: Measurement of serum concentrations of testosterone and dehydroepiandrosterone sulfate.;Hirsutism. Timepoint: Before and after the intervention. Method of measurement: Modified Ferriman-Gallwey questionnaire.;Sleep quality. Timepoint: Before and after the intervention. Method of measurement: Petersburg sleep quality questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Magnesium. Timepoint: Before and after the intervention. Method of measurement: Serum magnesium. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMahsa Gholizadeh Moghaddam
Esfahan University of Medical Sciences
Outcome results
None listed